Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions

British Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2000, Pages 244-253

  Ohyama, K ^a   Nakajima, M ^a   Suzuki, M ^a   Shimada, N ^b   Yamazaki, H ^a   Yokoi, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

Amiodarone; Cytochrome P450; Desethylamiodarone; Inactivation; Inhibition

Indexed keywords

AMIODARONE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DEETHYLAMIODARONE; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; PHENACETIN O DEETHYLASE;

ARTICLE; B LYMPHOBLAST; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MICROSOME; PRIORITY JOURNAL;

AMIODARONE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; TUMOR CELLS, CULTURED;

EID: 0034015751     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00134.x     Document Type: Article

References (46)

1. 1 Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43: 69-110.
2. 2 Kannan R, Nademanee K, Hendrickson JA, Rostami HJ, Singh BN. Amiodarone kinetics after oral doses. Clin Pharmacol 1982; 31: 438-444.
3. 3 Stäubli M, Bircher J, Galeazzi RL, Remund H, Studer H. Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol 1983; 24: 485-494.
4. 4 Holt DW, Tucker GT, Jacson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840-847.
5. 5 Andreasen F, Agerbæk H, Bjerregaard P, Gøtzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981; 19: 293-299.
6. 6 Trivier J-M, Libersa C, Belloc C, Lhermitte M. Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P4503A enzymes (first report). Life Sci 1993; 52: 91-96.
7. 7 Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21: 978-985.
8. 8 Heger JJ, Prystowsky EN, Zipes DP. Relationship between amiodarone dosage, drug concentrations, and adverse side effect. Am Heart J 1983; 106: 931-935.
9. 9 Marchiset D, Bruno R, Djiane P, et al. Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. Biopharm Drug Dispos 1985; 6: 209-215.
10. 10 Stäubi M, Troendle A, Schmid B, et al. Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol 1985; 29: 417-423.
11. 11 Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequence, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
12. 12 Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther 1989; 46: 43-50.
13. 13 O'Reilly RA, Tranger WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in human. Clin Pharmacol Ther 1987; 42: 290-294.
14. 14 Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992; 51: 398-407.
15. 15 Funck-Brentano C, Jacqz-Aigrain E, Leenhardt A, et al. Influence of amiodarone on genetically determined drug metabolism in humans. Clin Pharmacol Ther 1991; 50: 259-266.
16. 16 Funck-Brentano C, Becquemont L, Kroemer KH, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55: 256-269.
17. 17 Nicolau DP, Uber WE, Crumbley AJ III, Strange C. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992; 11: 564-568.
18. 18 Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother 1993; 27: 569-571.
19. 19 Smith G, Stubbins J, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998; 28: 1129-1165.
20. 20 Walker DK, Alabaster CT, Congrave GS, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. Drug Metab Dispos 1996; 24: 447-454.
21. 21 Jaruratanasirikul S, Hortiwakul R. The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes. J Pharm Pharmacol 1994; 46: 953-955.
22. 22 Larry D, Funk-Brentano C, Breil P, et al. Effect of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983; 32: 1063-1068.
23. 23 Ohmori S, Ishii I, Kuriya S, et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rat. Drug Metab Dispos 1993; 21: 358-363.
24. 24 Khojasteh-Bakht SC, Koenigs LL, Peter RM, Trager WF, Nelson SD. (R) -( + )-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab Dispos 1998; 26: 701-704.
25. 25 He K, Iyer RK, Hayes NR, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252-259.
26. 26 Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1993; 3: 363-371.
27. 27 He K, Woof TF, Hollenberg F. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). Drug Metab Dispos 1999; 288: 791-797.
28. 28 Nakajima M, Kobayashi K, Shimada N, et al. Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 1998; 46: 55-62.
29. 29 Kobayashi K, Nakajima M, Chiba K, et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 1998; 45: 361-368.
30. 30 Yamazaki H, Tanaka M, Shimada T. Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethxycoumarin O-deethylation by human liver cytochrome P450 enzyme. J Chromatogr B Biomed Appl 1999; 721: 13-19.
31. 31 Lang D, Döcker R. Highly sensitive and specific high-performance liquid chromatograghic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 1995; 672: 305-309.
32. 32 Nakajima M, Inoue T, Shimada N, et al. Cytochrome P4502C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26: 261-266.
33. 33 Court MH, Von-Moltke LL, Shader RI, Greenblatt DJ. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 1997; 18: 213-226.
34. 34 Arlotto MP, Trant JM, Estabrook RW. Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Meth Enzymol 1991; 206: 454-462.
35. 35 Segel IH. Rapid equilibrium partial and mixed-type inhibition. In Enzyme Kinetics. New York: A Wiley-Interscience Publication, 1993: 161-226.
36. 36 Silverman RB. Mechanism-based enzyme inactivation. In Chemistry and Enzymology, Vol 1. Boca Raton: CRC Press., 1988: 3-30.
37. 37 Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alteration caused by drug-drug Interactions: Metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-411.
38. 38 Lalloz MRA, Byfield PGH, Greenwood RM, Himsworth RL. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J Pharm Pharmacol 1984; 36: 366-372.
39. 39 Berger Y, Harris L. Pharmacokinetics. In Amiodarone: Pharmacology, Pharmacokinetics, Toxicology, and Clinical Effects, eds. Harris L, Roncucci R. Paris: Medecine et Science Internationales, 1986: 45-98.
40. 40 Latini R, Tognoni G, Kates ER. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984; 9: 136-156.
41. 41 Jafari-Fesharaki M, Scheinman MM. Adverse effect of amiodarone. Pace 1998; 21: 108-120.
42. 42 Somogyi A, Muirhead M. Pharmacokinetic interaction of cimetidine. Clin Pharmacokinet 1987; 12: 321-366.
43. 43 Larrey D, Tinel M, Letteron P, et al. Formation of an inactive cytochrome P-450Fe (II)-metabolite complex after administration of amiodarone in rats, mice and hamsters. Biochem Pharmacol 1986; 35: 2213-2220.
44. 44 Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995; 275: 1527-1535.
45. 45 Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993; 6: 649-656.
46. 46 Hirsch A, Saccar C, McGeady SJ. Interaction between theophylline and amiodarone. Ann Allergy 1993; 70: 68.